Related Experiment Videos
Induction of canine in vitro reactivity to alloantigen following intralymphatic immunization
An experimental model has been developed using the dog to study the induction of systemic cell-mediated immunity following intralymphatic immunization (ILI) with allogenic cells. As detected in one-way mixed lymphocyte cultures, blastogenically-reactive immune peripheral blood lymphocytes were observed after the third ILI with 10(7) cells. The in vitro reactivity was augmented by a fourth ILI to a node not previously injected indicating that a response in one node was followed by the trafficing of memory cells to other nodes. No immune PBL were detected after four ILI with lower doses of 10(3) cells. However, these dogs subsequently responded to a single injection of 10(7) cells with high levels of immune lymphocytes which were detectable for up to 24 days. Apparently, ILI with 10(3) or 10(5) cells, while insufficient to produce detectable levels of alloreactive lymphocytes were sufficient for lymphocyte priming. Results obtained with this model will aid in ongoing human trials of intralymphatic immunotherapy of malignant disease.
An experimental model has been developed using the dog to study the induction of systemic cell-mediated immunity following intralymphatic immunization (ILI) with allogenic cells. As detected in one-way mixed lymphocyte cultures, blastogenically-reactive immune peripheral blood lymphocytes were observed after the third ILI with 10(7) cells. The in vitro reactivity was augmented by a fourth ILI to a node not previously injected indicating that a response in one node was followed by the trafficing of memory cells to other nodes. No immune PBL were detected after four ILI with lower doses of 10(3) cells. However, these dogs subsequently responded to a single injection of 10(7) cells with high levels of immune lymphocytes which were detectable for up to 24 days. Apparently, ILI with 10(3) or 10(5) cells, while insufficient to produce detectable levels of alloreactive lymphocytes were sufficient for lymphocyte priming. Results obtained with this model will aid in ongoing human trials of intralymphatic immunotherapy of malignant disease.